{"url":"https://newsforagent.com/news/2026-11-03/neural-therapeutics-cwe-non-binding-deal","markdown_url":"https://newsforagent.com/news/2026-11-03/neural-therapeutics-cwe-non-binding-deal.md","title":"Neural Therapeutics CWE Deal Still Non-Binding","headline":"Neural Therapeutics' Bid for CWE's Remaining 69.25% Remains Non-Binding as May 31 Deadline Passes","description":"Neural Therapeutics' plan to buy CWE's remaining 69.25% stake stays non-binding after the May 31, 2026 deadline passed.","section":"Mergers & Acquisitions","published_at":"2026-11-03T01:54:19+00:00","modified_at":"2026-11-03T01:54:19+00:00","author":"News Desk","key_takeaways":["Neural Therapeutics is seeking CWE European Holdings' remaining 69.25% stake on a non-binding basis, with no binding commitment in place.","The May 31, 2026 completion deadline for the CWE acquisition has passed.","Chairman John Durfy resigned on October 26, 2026, during the ongoing transaction discussions."],"companies":[{"name":"Neural Therapeutics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00026wi/neural-therapeutics","website":"https://www.neuraltherapeutics.ca"}],"source":{"publisher":"TradingView","title":"Neural Therapeutics Inc. (NURL) CWE Deal Remains Non-Binding, Requires Financing","url":"https://www.tradingview.com/news/tradingview:aec237bcdaa68:0-neural-therapeutics-inc-nurl-cwe-deal-remains-non-binding-requires-financing/"},"other_sources":[],"tags":["Mergers & Acquisitions","Neural Therapeutics"],"body_markdown":"[Neural Therapeutics](https://akta.pro/company-profiles/00026wi/neural-therapeutics) Inc. is pursuing the remaining 69.25% of CWE European Holdings Inc. on a non-binding basis, with no binding commitment in place and a May 31, 2026 completion deadline that has passed. [TradingView](https://www.tradingview.com/news/tradingview:aec237bcdaa68:0-neural-therapeutics-inc-nurl-cwe-deal-remains-non-binding-requires-financing/) reported the status of the proposed acquisition. Neural Therapeutics is a Toronto-based public company founded in 2020, according to [akta.pro company records](https://akta.pro/company-data). CWE European Holdings operates the Hanf.com CBD business in Germany.\n\n## Neural Therapeutics' Non-Binding CWE Stake Purchase\n\nNeural Therapeutics already holds 30.75% of CWE European Holdings, and completing the proposed acquisition would raise its ownership above that level. The company said efforts to acquire the remaining 69.25% are advancing on a non-binding basis. Completion depends on CWE financing and regulatory approvals, and no binding commitment exists. The May 31, 2026 deadline for completion has passed, and the release provides no revised binding timetable. Chairman John Durfy resigned on October 26, 2026, a board leadership departure during the ongoing transaction discussions.\n\n## Hanf.com Revenue and Store Network\n\nNeural Therapeutics signed a non-binding letter of intent in October 2024 to acquire an interest in CWE European Holdings, the operator of the Hanf.com chain of 12 physical and online stores in Bavaria, Germany, according to akta.pro company records. Hanf.com reported preliminary unaudited fiscal 2025 revenue of CAD $11.2 million (€7.1 million), about 58% growth from CAD $7.1 million in fiscal 2024. Normalized operating income for Hanf.com in fiscal 2025 was CAD $280,000 after excluding non-recurring costs. The same records list a 19-store Hanf.com retail network across Germany, including 11 directly owned stores and 4 franchises, plus 2 new stores in Bielefeld and Herford.\n\n## CSE Approval and Earlier CWE Steps\n\nIn August 2026, Neural Therapeutics received conditional approval from the Canadian Securities Exchange for its acquisition of the remaining equity in CWE European Holdings, which operates the Hanf.com CBD business in Germany, Newsfile reported. In February 2026, the company applied to the Canadian Securities Exchange for approval to acquire the remaining 69.25% of CWE European Holdings through the Series B Transactions, with 99.89% shareholder approval obtained at the May 2026 AGSM and a concurrent CAD $1 million convertible debenture financing, according to akta.pro company records. In June 2026, Neural Therapeutics announced it would voluntarily move from quarterly to semi-annual financial reporting under a Canadian Securities Administrators pilot program (CBO 51-933), effective for the three- and nine-month period ended April 30, 2026, Newsfile reported.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}